Latest Surmodics Inc (SRDX) Headlines Q4 Loss W
Post# of 37
Posted On: 03/13/2014 2:19:04 PM
Latest Surmodics Inc (SRDX) Headlines
Q4 Loss Widens at Amedisys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:00AM CDT
Amedisys recorded adjusted loss from continuing operations per share of 5 cents in the fourth quarter of 2013.
Updated Research Report on Abaxis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:20PM CDT
On Mar 11, 2014, we issued an updated research report on Abaxis.
GW Pharmaceuticals (GWPH) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:18AM CDT
GW Pharmaceuticals plc (GWPH) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
Agios Pharmaceuticals (AGIO) in Focus: Stock Tumbles 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:48AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session,reversing the recent trend for AGIO as the stock is now up around 37.7% in the past one-month time frame.
Coverage Initiated on ResMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:07PM CDT
On Mar 10, 2014, we initiated coverage on ResMed, Inc.
Covidien Next-Gen Ventilator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 4:40PM CST
In a couple of trading days following the announcement, Covidien's stock rose 0.7% to close at $71.40 yesterday.
INSYS Therapeutics (INSY) Soars: Stock Adds 21.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:39AM CST
INSYS Therapeutics, Inc. was a big mover last session, as its shares rose just nearly 22% on the day.
Weakness Seen in ICU Medical (ICUI) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:59AM CST
ICU Medical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
SurModics Elects Additional Board Members
Close-Up Media - Thu Feb 20, 11:39PM CST
SurModics, Inc., a provider of surface modification and in vitro diagnostic technologies to the healthcare industries, has announced the addition of two independent members, Ronald Kalich and Timothy Nelson, to its board of directors, effective immediately.
SurModics Announces Changes to Board of Directors
Business Wire - Tue Feb 18, 6:00PM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the addition of two independent members, Ronald Kalich and Timothy Nelson, to its board of directors, effective immediately. The Company also announced the resignation of current board member, Mary Brainerd. With these changes, the SurModics board consists of nine members, eight of whom are independent.
SurModics to Present at RBC Capital Markets Global Healthcare Conference
Business Wire - Tue Feb 18, 7:00AM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the RBC Capital Markets Global Healthcare Conference on Tuesday, February 25, 2014, at 9 a.m. ET (8 a.m. CT) in New York City.
Should You Get Rid of Abaxis (ABAX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:30AM CST
It is time to get rid of Abaxis, as it has witnessed a significant price decline in the past four weeks and has seen negative earnings estimate revisions
Marginal Earnings Beat at SurModics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 10:30AM CST
SurModics' first quarter fiscal 2014 adjusted earnings beat the Zacks Consensus Estimate by a penny.
SurModics Reports First Quarter Fiscal 2014 Results
Business Wire - Thu Jan 30, 3:00PM CST
--Pro Forma EPS Increases 17% to $0.21 per share on 5% Pro Forma Revenue Rise in Q1 2014
SurModics to Webcast Shareholders Annual Meeting on February 4
Business Wire - Wed Jan 22, 7:00AM CST
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, February 4, at 4:00 p.m. CT (5:00 p.m. ET).
SurModics to Webcast First Quarter 2014 Earnings Conference Call on January 30
Business Wire - Tue Jan 21, 7:00AM CST
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter 2014 conference call on Thursday, January 30, at 4:00 p.m. CT (5:00 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
SurModics Inc's VP & CFO to give presentation at Oppenheimer Healthcare Conference in New York City
M2 - Thu Dec 05, 10:33AM CST
SurModics Inc (NasdaqGS:SRDX) stated on Wednesday that it will take part at the Oppenheimer Healthcare Conference scheduled for 11 December 2013 at 8:30 CT (9:30 ET) in New York City.
Bear of the Day: SurModics (SRDX) - Bear of the Day
Kevin Cook - Zacks Investment Research - Wed Dec 04, 10:07AM CST
Bear of the Day: SurModics (SRDX) - Bear of the Day
SurModics to Present at Oppenheimer Healthcare Conference
Business Wire - Wed Dec 04, 7:00AM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Oppenheimer Healthcare Conference on Wednesday, December 11, 2013, at 8:30 a.m. CT (9:30 a.m. ET) in New York City.
Q4 Loss Widens at Amedisys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:00AM CDT
Amedisys recorded adjusted loss from continuing operations per share of 5 cents in the fourth quarter of 2013.
Updated Research Report on Abaxis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:20PM CDT
On Mar 11, 2014, we issued an updated research report on Abaxis.
GW Pharmaceuticals (GWPH) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:18AM CDT
GW Pharmaceuticals plc (GWPH) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
Agios Pharmaceuticals (AGIO) in Focus: Stock Tumbles 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:48AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session,reversing the recent trend for AGIO as the stock is now up around 37.7% in the past one-month time frame.
Coverage Initiated on ResMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:07PM CDT
On Mar 10, 2014, we initiated coverage on ResMed, Inc.
Covidien Next-Gen Ventilator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 4:40PM CST
In a couple of trading days following the announcement, Covidien's stock rose 0.7% to close at $71.40 yesterday.
INSYS Therapeutics (INSY) Soars: Stock Adds 21.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:39AM CST
INSYS Therapeutics, Inc. was a big mover last session, as its shares rose just nearly 22% on the day.
Weakness Seen in ICU Medical (ICUI) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:59AM CST
ICU Medical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
SurModics Elects Additional Board Members
Close-Up Media - Thu Feb 20, 11:39PM CST
SurModics, Inc., a provider of surface modification and in vitro diagnostic technologies to the healthcare industries, has announced the addition of two independent members, Ronald Kalich and Timothy Nelson, to its board of directors, effective immediately.
SurModics Announces Changes to Board of Directors
Business Wire - Tue Feb 18, 6:00PM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the addition of two independent members, Ronald Kalich and Timothy Nelson, to its board of directors, effective immediately. The Company also announced the resignation of current board member, Mary Brainerd. With these changes, the SurModics board consists of nine members, eight of whom are independent.
SurModics to Present at RBC Capital Markets Global Healthcare Conference
Business Wire - Tue Feb 18, 7:00AM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the RBC Capital Markets Global Healthcare Conference on Tuesday, February 25, 2014, at 9 a.m. ET (8 a.m. CT) in New York City.
Should You Get Rid of Abaxis (ABAX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:30AM CST
It is time to get rid of Abaxis, as it has witnessed a significant price decline in the past four weeks and has seen negative earnings estimate revisions
Marginal Earnings Beat at SurModics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 10:30AM CST
SurModics' first quarter fiscal 2014 adjusted earnings beat the Zacks Consensus Estimate by a penny.
SurModics Reports First Quarter Fiscal 2014 Results
Business Wire - Thu Jan 30, 3:00PM CST
--Pro Forma EPS Increases 17% to $0.21 per share on 5% Pro Forma Revenue Rise in Q1 2014
SurModics to Webcast Shareholders Annual Meeting on February 4
Business Wire - Wed Jan 22, 7:00AM CST
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, February 4, at 4:00 p.m. CT (5:00 p.m. ET).
SurModics to Webcast First Quarter 2014 Earnings Conference Call on January 30
Business Wire - Tue Jan 21, 7:00AM CST
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter 2014 conference call on Thursday, January 30, at 4:00 p.m. CT (5:00 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
SurModics Inc's VP & CFO to give presentation at Oppenheimer Healthcare Conference in New York City
M2 - Thu Dec 05, 10:33AM CST
SurModics Inc (NasdaqGS:SRDX) stated on Wednesday that it will take part at the Oppenheimer Healthcare Conference scheduled for 11 December 2013 at 8:30 CT (9:30 ET) in New York City.
Bear of the Day: SurModics (SRDX) - Bear of the Day
Kevin Cook - Zacks Investment Research - Wed Dec 04, 10:07AM CST
Bear of the Day: SurModics (SRDX) - Bear of the Day
SurModics to Present at Oppenheimer Healthcare Conference
Business Wire - Wed Dec 04, 7:00AM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Oppenheimer Healthcare Conference on Wednesday, December 11, 2013, at 8:30 a.m. CT (9:30 a.m. ET) in New York City.
(0)
(0)